![](/documents/10803/401463/business-dev-banner.jpg/15ce6a7d-1239-a859-f7f3-cd97e2958be5?t=1618260117952)
Business Development Office
The Business Development Office (BDO) at the Research Institute of the McGill University Health Centre (RI-MUHC) assists researchers in finding funding opportunities, identifying and pursuing commercialization opportunities, and creating partnerships.
Business development services
Services offered by the Business Development Office (BDO) include:
Funding opportunities
- We match research teams with grant opportunities aligned with their science
- We assist with leveraging and obtaining matching funds
Business development and commercialization
- We identify market opportunities for novel technologies
- We facilitate technology transfer and the creation of start-up companies
- We conduct competitive benchmarking analyses
- We work with researchers to acquire proof-of-concept funds
Creating partnerships
- We secure funding through partnerships with industry, government and non-profits
- We maintain relationships with hospital foundations and other non-traditional funding agencies
Success stories
These are just a few examples of recent successes in business development at the RI-MUHC.
![Collaborating with industry to develop lipid nanoparticles Collaborating with industry to develop lipid nanoparticles](/documents/10803/16235478/ar-2023-home-biz-dev.jpg/a4ba434a-ab14-730c-4024-ff415da84c55?t=1690470982549)
Collaborating with industry to develop lipid nanoparticles
Julia Burnier, PhD, a scientist in the Cancer Research Program at the Research Institute of the McGill University Health Centre (RI-MUHC), was selected to collaborate with ModernaTX Inc. for a sponsored research project in the area of lipid nanoparticles (LNPs)...
![Bringing a C-diff predictive biomarker kit into clinical practice Bringing a C-diff predictive biomarker kit into clinical practice](/documents/10803/8630830/ar-2022-home-biz-dev.jpg/a2eda96e-74b8-d052-547d-cf6f92160bd0?t=1664890700212)
Bringing a C-diff predictive biomarker kit into clinical practice
The COVID-19 pandemic has focused attention on public health and hospital practices. These practices are important not only for the management of COVID-19, but also for minimizing the impact of other harmful infectious agents, such as Clostridioides difficile...
![Precision screening tool for early diagnosis of ovarian and endometrial cancers developed through innovative partnerships Precision screening tool for early diagnosis of ovarian and endometrial cancers developed through innovative partnerships](/documents/10803/2809062/business-dev-thumbnail.jpg/b2c5a215-d672-45f4-1511-951777937f18?t=1617900674877)
Precision screening tool for early diagnosis of ovarian and endometrial cancers developed through innovative partnerships
Together, ovarian and endometrial cancers represent the fourth leading cause of cancer-related deaths among Canadian women. Although more than 80% of these patients can be cured if their cancer is detected early, most women are only diagnosed after the cancer...
![Bringing an innovative retinal gene therapy to clinic Bringing an innovative retinal gene therapy to clinic](/documents/10803/3585170/ar-2018-business-dev-thumbnail.jpg/66a50611-609c-4abe-7a7b-a820725a4910?t=1623085750517)
Bringing an innovative retinal gene therapy to clinic
Imagine a world devoid of colour, a world where the smile of a loved one is indistinguishable from a black abyss. This world is the everyday reality for people suffering from Zellweger spectrum disorder (ZSD). Affecting around 2,000 people worldwide...
![New target for cystic fibrosis drug development: Ceramides New target for cystic fibrosis drug development: Ceramides](/documents/10803/3588875/ar-2017-business-dev-thumbnail.jpg/f149ce37-9701-960f-cfc5-6ccaf22228be?t=1623247332141)
New target for cystic fibrosis drug development: Ceramides
Cystic fibrosis (CF) is a deadly respiratory disease characterized by thick mucus in the lungs. This mucus becomes colonized by pathogens and initiates a vicious cycle of infection and inflammation. Although no effective therapeutic options for CF exist...
Contact us
![](/documents/10803/401463/business-dev-contact.jpg/980a1511-ce9a-a062-9e4c-e100e718d79b?t=1622820103371)
We welcome inquiries about Business Development Office services. Please email us: business.development@rimuhc.ca